Latest International Expansion News

AUB Group has successfully raised AUD 400 million through an institutional placement to fund its acquisition of Prestige and support future growth. A complementary AUD 40 million Share Purchase Plan will also be offered to eligible shareholders.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

XRF Scientific is set to open a new office in India, shifting from a distributor model to direct presence to capture growing demand in mining and industrial sectors. This move aims to strengthen sales and customer trust in one of the world’s fastest-growing economies.

AML3D Limited has reported a remarkable 360% increase in customer receipts for the December 2025 quarter, driven by strong demand from the US defence sector and a robust order book of A$16.5 million for FY26. The company is accelerating its US scale-up strategy while expanding into UK and European defence markets.

Talius Group reported a positive operating cash flow for the December quarter, alongside a 3% rise in subscriptions and a $4 million capital placement. The company also announced a CEO succession and expanded its international footprint with new pilot programs.

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Pureprofile Limited has upgraded its FY26 revenue guidance after a record first half, driven by strong international growth and a booming platform business. The Rest of World segment now outpaces ANZ, signalling a major shift in the company’s geographic footprint.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

ReadCloud Limited has secured over 50 new school contracts for 2026, driving strong growth in its VET-in-Schools and eBooks divisions despite ongoing funding challenges in its Industry Training segment.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.